PIPELINE

Lead programme

LEAD PROGRAMME

CMD002 — KRAS G12V oncology

CMD001 is our lead programme: a first-in-class intracellular antibody designed to engage KRAS G12V directly in the cytoplasm of cancer cells. The programme is at Phase I ready stage, with clinical entry planned in the near term.

INDICATIONS

One mutation. Four cancers.

KRAS G12V is a single point mutation that drives oncogenic signalling across multiple cancers. Our exclusive rights cover all four major tumor types in which G12V is a significant driver:

Pancreatic cancer
Colorectal cancer
Lung cancer (non-small cell)
Liver cancer